hClock gene expression in human colorectal carcinoma

  • Authors:
    • Liying Wang
    • Bozan Chen
    • Yaping Wang
    • Ning Sun
    • Chao Lu
    • Ruizhe Qian
    • Luchun Hua
  • View Affiliations

  • Published online on: August 16, 2013     https://doi.org/10.3892/mmr.2013.1643
  • Pages: 1017-1022
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In this study, we aimed to investigate changes in the expression of human Clock (hClock), a gene at the core of the circadian gene family, in colorectal carcinomas (CRCs) and to discuss the possible effects. Previous studies have revealed that the disruption of circadian rhythms is one of the endogenous factors that contribute to the initiation and development of CRCs. However, the underlying molecular changes to the circadian genes associated with CRCs have not been explored. Immunofluorescence and quantitative polymerase chain reaction (qPCR) analysis of the hCLOCK protein and gene expression were performed in 30 cases of CRC. The hCLOCK protein was expressed in all specimens obtained from 30 CRC patients. Higher levels of hCLOCK expression were observed in human CRC tissues compared with the paired non-cancerous tissues. hCLOCK expression was significantly higher in poorly differentiated, or late-stage, Dukes' grade tumors and in 64.3% of tumor cases with lymph node metastasis. The hClock gene was expressed in all specimens. A significantly higher expression of hClock was found in human CRC cases compared with paired non-cancerous tissues. There was a strong positive linear correlation between hClock gene expression and protein expression in human CRCs. A strong positive linear correlation was also found between hClock gene expression and ARNT, HIF-1α and VEGF expression in human CRCs. There was no significant correlation between hClock and Bak, Bax, Bid, tumor necrosis factor receptor I (TNFR I) and TNFR II. The circadian gene hClock was stably expressed in human colorectal mucosa and was important in regulating the expression of downstream clock-controlled genes. hCLOCK may interact with HIF-1α/ARNT and activate VEGF to stimulate tumor angiogenesis and metastasis.

Introduction

The circadian gene network sets and regulates the circadian rhythms in organisms as oscillations with an approximate 24 h cycle (1). At the molecular level, circadian rhythms are controlled by the interaction between positive and negative feedback loops consisting of several key clock regulators (2,3). A model encompassing a feedback system involving heterodimer transcriptional factors (Clock and Bmal1), two cryptochromes (Cry1 and Cry2), and three Period (Per1, Per2, and Per3) regulators has been widely described. Among these clock genes, hClock is at the core of the circadian gene family.

Previous studies have revealed that the disruption of circadian rhythms is one of the endogenous factors that contributes to the initiation and development of colorectal carcinoma (CRC). Krugluger et al reported that the expression of hPer1 mRNA in CRCs was lower than that found in normal cells (4). Wang et al detected that the expression of the hPer2 protein in CRC cells was lower than that in non-cancerous cells (5). Correlations between the decreased hPer2 level and the patient’s age, histological grade and TNM stage were also detected. The human Clock (hClock) gene functions upstream of hPer2 to regulate its expression (5). Therefore, the circadian hClock gene may play a vital role in the development of CRC.

Hoffman et al observed that the hCLOCK protein expression level was approximately two times higher in breast tumor cells compared with that observed in the adjacent normal tissues and three times higher than that in normal breast cells (6). Alhopuro et al reported that ~53% of hClock genes in CRC cells had point mutations in the DNA sequence (7). Oshima et al demonstrated that the expression level of hClock mRNA in CRC cells was significantly higher compared with that found in normal tissues (8).

CRC is one of the most commonly observed malignancies and is the leading cause of cancer-associated mortality worldwide (9). In 2011, ~141,210 new CRC cases and 49,380 mortalities were predicted in the USA (10). In China, CRC is the fourth leading cause of cancer mortality in large cities and the fifth in more rural areas. However, in Shanghai, the incidence of CRC and its mortality rate ranked second and third, respectively, for females (11). As surgical approaches and conventional therapeutics have been incapable of fully controlling the outcomes of CRC, there is an urgent need to develop more effective treatments.

The circadian rhythm is interconnected with many aspects of cellular function, such as cell proliferation, migration and differentiation, and it also helps regulate the digestive system (12,13). The molecular mechanism governing the development of CRC is a multiple factor and multistep process, yet the molecular changes underlying it remain unexplored. The core circadian gene, hClock, may participate in the development of CRC, but the correlation between them has not been reported.

In this study, immunofluorescent histochemistry and quantitative polymerase chain reaction (qPCR) were used to characterize the role of hClock in the development of human CRC. The correlation between the hClock gene and tumor-related genes Bak, Bax, Bid, HIF-1α, ARNT, tumor necrosis factor receptor I (TNFR I), TNFR II and VEGF were also examined. Based on our data, the expression of hClock in human CRCs and its possible effects were discussed. Our investigation may provide a new angle for understanding tumorigenesis and a new target for CRC treatment development.

Materials and methods

Tissue samples

In total, 30 specimens were obtained from the Tumor Tissue Bank of the Center of Pathological Research in the Institutes of Biomedical Sciences at Fudan University (Shanghai, China). The specimens were obtained from patients who had undergone a radical CRC resection between January 2007 and September 2008 from the General Surgery Department of Huashan Hospital Affiliated to Fudan University (Shanghai, China). The specimens were all obtained between 10:00 am–14:00 pm. The cancerous tissue was dissected from the cancerous mucosa while the paired non-cancerous tissue was obtained from the normal section of the colorectal mucosa of the same patient. All tumor tissues were pathologically confirmed as CRC and the patients did not receive any presurgical treatment nor exhibited any metastasis. Following surgical removal, samples were immediately preserved in liquid nitrogen and stored at −80°C. Complete medical records including the patient’s age, tumor site, tumor type, histological grade and Dukes’ stage were also obtained. This study was approved by the Medical Ethics Committee of Huashan Hospital, Fudan University, Shanghai, China. Written informed consent was obtained from the patients.

Immunofluorescent histochemistry

Frozen tissues were cut into 6 μm sections and stored at −80°C. Sections were fixed at 4°C with 70% ethanol solution and blocked by 10% normal goat serum solution at 37°C for 60 min. Subsequently, sections were incubated with goat anti-human hClock antibody (1:50, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) as the primary antibody at 4°C overnight. Following a brief wash with PBS, secondary donkey anti-goat IgG fluorescent antibody (1:200; Invitrogen Life Technologies, Carlsbad, CA, USA) was added for 2 h at room temperature. Following several washes with PBS, the slides were mounted. Sections which were only incubated with 10% normal goat serum solution, served as negative controls. The image analysis software Image-Pro Plus (Media Cybernetics, Rockville, MD, USA) was used to measure the Integrated Optical Density (IOD), which is the cumulative OD of the positive immunofluorescent expression of a selected area and represents the total protein expression of that area.

RNA extraction and first-strand cDNA synthesis

Preparation of total RNA from tissue samples was performed using the TRIzol reagent (Invitrogen Life Technologies). The quantity of total RNA was determined using UV spectrophotometry and RNA integrity was assessed using agarose gel electrophoresis. First-strand cDNA was prepared with oligo-dT primers using a commercial cDNA synthesis kit (ReverTra Ace qPCR RT kit, Toyobo, Osaka, Japan). The cDNA was subsequently amplified for 33 cycles with specific primers for Bak, Bax, Bid, HIF-1α, ARNT, TNFR I, TNFR II and VEGF. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as an internal reference (Table I). Sequence data were analyzed using the basic local alignment search tool (BLAST) on the National Centre for Biotechnology Information (NCBI) website (http://www.ncbi.nlm.nih.gov).

Table I

Primer pairs used for qPCR.

Table I

Primer pairs used for qPCR.

GenePrimer (5′-3′)Product length (bp)
hClockForward: GGCTGAAAGACGACGAGAAC
Reverse: GGTGTTGAGGAAGGGTCTGA
210
ARNTForward: CAAGCCCCTTGAGAAGTCAG
Reverse: GGGGTAGGAGGGAATGTGTT
165
BakForward: GGGTCTATGTTCCCCAGGAT
Reverse: AATGGGAGCAGGGGTAGAGT
165
BaxForward: TCTGACGGCAACTTCAACTG
Reverse: TTGAGGAGTCTCACCCAACC
188
BidForward: GAGGATTGTGGCCTTCTTTG
Reverse: CTCAGCCCAGACTCACATCA
185
HIF-1αForward: GAAAGCGCAAGTCCTCAAAG
Reverse: TGGGTAGGAGATGGAGATGC
167
TNFR IForward: GTGCCTACCCCAGATTGAGA
Reverse: TGTCGATTTCCCACAAACAA
175
TNFR IIForward: GAGTTGTGGAAAGCCTCTGC
Reverse: CAGGGGGAGAAACAAACAAA
193
VEGFForward: AAGGAGGAGGGCAGAATCAT
Reverse: ATCTGCATGGTGATGTTGGA
226
GAPDHForward: ACAGCCGCATCTTCTTGTGCAGTA
Reverse: GGCCTTGACTGTGCCGTGAATTTT
226

[i] qPCR, quantitative polymerase chain reaction; TNFR, tumor necrosis factor receptor.

PCR reactions containing SYBR-green were amplified on a Corbett Real Time PCR machine (Bio-Rad, Hercules, CA, USA). Following reverse transcription, the cDNA was diluted to 10 ng/μl. The PCR reaction mixture contained 4 μl of diluted cDNA, 1 μl of 10 μM primers (0.5 μl of upstream primers, 0.5 μl of downstream primers), 10 μl SYBR Green Realtime PCR Master mix (Bio-Rad) and 5 μl of H2O, into a final volume of 20 μl. The samples were subjected to 40 cycles of amplification (denaturation at 95°C for 15 sec, primer annealing for 30 sec and extension at 72°C for 30 sec).

Following each qPCR, melting profiles were performed in order to rule out the possibilities of nonspecific PCR products and primer dimers. Data from the qPCR was represented by fluorescent intensity, ΔRn, and number of cycles. ΔRn=Rn+ − Rn, Rn+ refers to the fluorescent intensity of products at any time, Rn refers to the systematic basic fluorescent intensity (the fluorescent intensity at the 6–15th cycles). The threshold was set to the intermediate value of logΔRn vs. cycle function. The CT value stands for the number of cycles at the cross point of ΔRn vs. threshold. The higher the CT value, the greater the number of steady cycles, thus the lower the gene expression concentration. As the amplification efficiencies of the target genes and the internal control were equal, the relative changes to the target gene expression in the tumor cells compared with that in normal colorectal mucosa (ΔCT calibrator value) were calculated using the equation 2−ΔΔCT, where ΔΔCT = ΔCT(non-cancer) − ΔCT(cancer). The ΔCT values were determined by subtracting the average GAPDH CT value from the average target gene CT value.

Statistical analysis

Data are reported as the means ± SD. Comparison between the groups was performed using the paired Student’s t-test. Relative analysis was conducted using Pearson’s χ2 test. IBM SPSS Statistics 19.0 was used for all data analysis. P<0.01 was considered to indicate a statistically significant difference.

Results

Immunofluorescent histochemical analysis of hCLOCK protein expression

To analyze expression of the hClock gene in CRC, we first examined the expression of hCLOCK protein in 30 paired colorectal cancerous and non-cancerous tissues using immunofluorescent histochemistry. For these 30 cases, hCLOCK protein expression in colorectal tissues exhibited three typical patterns. Type I (11 cases): the immunofluorescence was markedly stronger in the cancerous cells compared with that in the paired non-cancerous cells, particularly in the nucleolus and cytoplasm. Type II (17 cases): there were no significant differences in the immunofluorescence between the cancerous and non-cancerous cells. Type III (2 cases): the immunofluorescence was stronger in the non-cancerous cells compared with that in the paired cancerous cells (Fig. 1).

In these 30 specimens, the average cumulative OD of the hCLOCK protein in cancerous tissues was 5389.59±2385.20 and that in paired non-cancerous tissues was 4558.34±1385.87, P<0.05 (P=0.034). These results revealed that the hCLOCK protein was expressed in all specimens and a higher expression level of hCLOCK protein was found in human CRCs compared with that in the paired non-cancerous tissues.

Correlation between hCLOCK protein expression and clinical-pathological features in CRC patients

In order to analyze the clinical and pathological relevance of high hCLOCK protein expression in human CRC, we assessed the correlation between hCLOCK expression and the respective clinical-pathological parameters in the 30 cases of CRC. As shown in Table II, an increased expression of hCLOCK protein was found more in male than female patients (P=0.039). We observed a higher expression of hCLOCK in poorly differentiated (P=0.042), or late-stage, Dukes’ grade (P=0.032) tumors. Furthermore, 64.3% of tumors with lymph node metastasis expressed higher hCLOCK levels. However, no correlations were found between high levels of hCLOCK expression and age, tumor site or pathology type.

Table II

Correlation between increased hCLOCK protein expression levels in CRC and clinical-pathological features.

Table II

Correlation between increased hCLOCK protein expression levels in CRC and clinical-pathological features.

Clinical-pathological featuresIncreased hCLOCK expression in tumorNon-increased hCLOCK expression in tumorP-value
Gender0.039
 Male811
 Female38
Tumor site>0.05
 Colon711
 Rectum48
Pathology type>0.05
 Ulcer611
 Protrude56
 Infiltrating02
Histological grade0.042
 I3
 I–II, II713
 II–III, III43
Dukes’ stage0.032
 001
 A04
 B47
 C77

[i] hCLOCK, human CLOCK, CRC, colorectal carcinoma.

Determination of hCLOCK mRNA level by qPCR

We further analyzed hClock mRNA levels in the 30 paired cancerous and non-cancerous tissues by qPCR. The quantity of hClock mRNA was normalized to the endogenous reference gene, GAPDH. The normalized hClock mRNA expression (ΔCt) of tumorous tissues was subsequently compared with the ΔCt of the paired non-tumorous tissues from the same CRC patient in order to determine their relative expression levels (ΔΔCt) (Fig. 2). The ΔCt of hClock in tumorous tissues (5.91±1.36) was significantly lower than that found in paired non-tumorous tissues (6.26±1.47; P=0.002), indicating a significantly higher level of hClock expression in human CRCs than in paired non-cancerous tissues.

Amongst the 30 specimens, 12 tumor tissues demonstrated a high expression of the hClock gene. Furthermore, in these 12 tumor tissues, 10 specimens also demonstrated a higher expression of the hCLOCK protein. The correlation coefficient (r) between hClock mRNA and the hCLOCK protein was 0.474, P<0.01 (P=0.008). The expression of the hClock gene and the hCLOCK protein revealed a strong positive linear correlation in human CRCs.

Correlation between the hClock gene and tumor-related genes

To further investigate the potential role of hClock at the molecular level, the correlation between the hClock gene and a number of tumor-related genes were determined by qPCR. As shown in Table III, there was a strong positive linear correlation between the hClock gene and the ARNT, HIF-1α and VEGF genes in human CRCs. There was no significant correlation between hClock with Bak, Bax, Bid, TNFR I and TNFR II. The higher expression of ARNT, HIF-1α and VEGF in poorly differentiated, or late-stage, Dukes’ grade tumors was observed. Furthermore, high VEGF expression was found in 14 tumor cases with lymph node metastasis.

Table III

Correlation between the hClock gene and other tumor-related genes.

Table III

Correlation between the hClock gene and other tumor-related genes.

Statistical significanceBakBaxBidHIF-1αARNTTNFR ITNFR IIVEGF
r0.1140.005−0.2720.5430.6080.370−0.2800.714
P-value0.5480.9800.4150.0460.0270.0680.0830.008

Discussion

It has been demonstrated that the circadian clock has important roles in orchestrating temporal integrations of physiology and behavior with the environment. This master clock, which resides in the hypothalamic suprachiasmatic nucleus in mammals, synchronizes multiple peripheral oscillators to ensure temporally coordinated physiology (1,14,15). Clocks located outside the brain, peripheral clocks, are important in regulating physiological functions and pathological situations.

Previous studies have suggested that the disruption of circadian rhythms, which are regulated by circadian genes, was one of the endogenous factors that contribute to tumor initiation and progression. Studies have reported evidence regarding the beneficial effects of chronotherapy, which refers to the delivery of chemotherapy according to the circadian rhythms (16,17). The hClock gene is at the core of the circadian gene family and directly, or indirectly, regulates certain clock-controlled genes (18,19). The role of hClock in human CRCs is unclear. In this study, we aimed to investigate this question directly. We first examined the protein expression of hCLOCK in CRC patients using immunofluorescent histochemistry. The results revealed that hCLOCK was expressed in all CRC specimens and there was a higher expression of hCLOCK in human CRC tissues compared with that found in the paired non-cancerous tissues (P=0.034).

We further analyzed hCLOCK expression patterns with the respective clinical-pathological features of these colorectal tumor tissues. We found that cancerous tissues with poorly differentiated (grade II or above), or late-stage, Dukes’ grade tumors (stage B or C) demonstrated increased expression of hCLOCK protein. The greater expression of hCLOCK in the CRC tissues of male patients compared with that in paired non-cancerous tissues was observed, but not in female patients. This may be further validated by using a larger sample set in the future.

qPCR analyses revealed that hClock was expressed in all of the specimens. A significantly higher level of hClock expression was found in human CRC compared with that in the paired non-cancerous tissue (P=0.002). hClock had a positive linear correlation with the hCLOCK protein in human CRCs (r=0.474, P=0.008). A higher expression of hClock was prevalent in tumor malignancies of a higher degree. These results suggested that the hClock is closely related to the development and prognosis of human CRCs.

We hypothesized that the circadian gene hClock may be a proto-oncogene. A proto-oncogene is usually a normal gene with rhythm, which is overexpressed and subsequently loses its rhythmic character in tumor cells. Hoffman et al observed deregulation of tumor-related genes in the hClock-silent cell strain, and that the protein hCLOCK expression in breast tumor cells was significantly higher compared with that in the adjacent normal tissues (6). Fu et al reported that c-myc in the tumorous cells of mice was regulated by circadian genes (20). The hClock gene correlated with cell cycles and had the characteristics of rhythmicity and specificity (21). This hypothesis requires further validation by examination with a larger sample set.

Circadian genes are important in regulating certain downstream clock-controlled genes (CCGs), including a variety of tumor-related genes (22). In our study, there was a significant positive linear correlation between the hClock gene and the ARNT, HIF-1α and VEGF genes in human CRCs. There was no significant correlation between hClock and Bak, Bax, Bid, TNFR I or TNFR II. Malignant tumors promote the secretion of various proangiogenic factors, of which the most important is VEGF. VEGF has a marked proangiogenic function and is closely related to tumor differentiation, Dukes’ stage tumors and tumors with lymph node metastasis.

When tumors were under environmental hypoxic conditions, the heterodimer HIF-1α/ARNT would be overexpressed, resulting in a higher VEGF expression. hClock may interact with HIF-1α/ARNT and activate VEGF to stimulate tumor angiogenesis and metastasis (23,24).

In conclusion, our data suggest that aberrant expression of hClock may correlate with the development and progression of CRCs. However, the mechanisms leading to a high expression of hClock in CRCs and how this promotes tumorigenesis remains unclear. Further studies using a larger sample set are required in order to elucidate the role of hClock in human CRCs.

Acknowledgements

This study was supported by the Natural Science Foundation of China (81070234 and 81000355).

References

1 

Panda S, Hogenesch JB and Kay SA: Circadian rhythms from flies to human. Nature. 417:329–335. 2002. View Article : Google Scholar : PubMed/NCBI

2 

Chen-Goodspeed M and Lee CC: Tumor suppression and circadian function. J Biol Rhythms. 22:291–298. 2007. View Article : Google Scholar

3 

Ko CH and Takahashi JS: Molecular components of the mammalian circadian clock. Hum Mol Genet. 15:R271–277. 2006. View Article : Google Scholar : PubMed/NCBI

4 

Krugluger W, Brandstaetter A, Kállay E, et al: Regulation of genes of the circadian clock in human colon cancer: reduced period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors. Cancer Res. 67:7917–7922. 2007. View Article : Google Scholar

5 

Wang Y, Hua L, Lu C and Chen Z: Expression of circadian clock gene human Period2 (hPer2) in human colorectal carcinoma. World J Surg Oncol. 9:1662011. View Article : Google Scholar : PubMed/NCBI

6 

Hoffman AE, Yi CH, Zheng T, et al: CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses. Cancer Res. 70:1459–1468. 2010. View Article : Google Scholar : PubMed/NCBI

7 

Alhopuro P, Björklund M, Sammalkorpi H, et al: Mutations in the circadian gene CLOCK in colorectal cancer. Mol Cancer Res. 8:952–960. 2010. View Article : Google Scholar : PubMed/NCBI

8 

Oshima T, Takenoshita S, Akaike M, et al: Expression of circadian genes correlates with liver metastasis and outcomes in colorectal cancer. Oncology reports. 25:1439–1446. 2011. View Article : Google Scholar : PubMed/NCBI

9 

Zheng S and Cai SR: Colorectal cancer epidemiology and prevention study in China. Chinese-German J Clin Oncol. 2:72–75. 2003. View Article : Google Scholar

10 

Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI

11 

Zheng S and Cai SR: Colorectal cancer epidemiology and prevention study in China. Chinese-German J Clin Oncol. 2:72–75. 2003. View Article : Google Scholar

12 

Zhang EE, Liu AC, Hirota T, et al: A genome-wide RNAi screen for modifiers of the circadian clock in human cells. Cell. 139:199–210. 2009. View Article : Google Scholar : PubMed/NCBI

13 

Scheving LA: Biological clocks and the digestive system. Gastroenterology. 119:536–549. 2000. View Article : Google Scholar

14 

Reppert SM and Weaver DR: Coordination of circadian timing in mammals. Nature. 418:935–41. 2002. View Article : Google Scholar : PubMed/NCBI

15 

Hirota T and Fukada Y: Resetting mechanism of central and peripheral circadian clocks in mammals. Zoolog Sci. 21:359–68. 2004. View Article : Google Scholar : PubMed/NCBI

16 

Innominato PF, Focan C, Gorlia T, et al: Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res. 69:4700–4707. 2009. View Article : Google Scholar : PubMed/NCBI

17 

Block KI, Block PB, Fox SR, et al: Making circadian cancer therapy practical. Integr Cancer Ther. 8:371–386. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Gekakis N, Stakins D, Nguyen HB, et al: Role of the CLOCK protein in the mammalian circadian mechanism. Science. 280:1564–1569. 1998. View Article : Google Scholar : PubMed/NCBI

19 

Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F and Okamura H: Control mechanism of the circadian clock for timing of cell division in vivo. Science. 302:255–259. 2003. View Article : Google Scholar : PubMed/NCBI

20 

Fu L, Pelicano H, Liu J, Huang P and Lee C: The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 111:41–50. 2002. View Article : Google Scholar : PubMed/NCBI

21 

Polidarová L, Soták M, Sládek M, Pacha J and Sumová A: Temporal gradient in the clock gene and cell-cycle checkpoint kinase Weel expression along the gut. Chronobiol Int. 26:607–620. 2009.PubMed/NCBI

22 

Gery S and Koeffler HP: The role of circadian regulation in cancer. Cold Spring Harb Symp Quant Biol. 72:459–464. 2007. View Article : Google Scholar

23 

Park JE, Lee DH, Lee JA, Park SG, Kim NS, Park BC and Cho S: Annexin A3 is a potential angiogenic mediator. Biochem Biophys Res Commun. 337:1283–1287. 2005. View Article : Google Scholar : PubMed/NCBI

24 

Chau NM, Rogers P, Aherne W, et al: Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors. Cancer Res. 65:4918–4928. 2005. View Article : Google Scholar

Related Articles

Journal Cover

October 2013
Volume 8 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang L, Chen B, Wang Y, Sun N, Lu C, Qian R and Hua L: hClock gene expression in human colorectal carcinoma. Mol Med Rep 8: 1017-1022, 2013
APA
Wang, L., Chen, B., Wang, Y., Sun, N., Lu, C., Qian, R., & Hua, L. (2013). hClock gene expression in human colorectal carcinoma. Molecular Medicine Reports, 8, 1017-1022. https://doi.org/10.3892/mmr.2013.1643
MLA
Wang, L., Chen, B., Wang, Y., Sun, N., Lu, C., Qian, R., Hua, L."hClock gene expression in human colorectal carcinoma". Molecular Medicine Reports 8.4 (2013): 1017-1022.
Chicago
Wang, L., Chen, B., Wang, Y., Sun, N., Lu, C., Qian, R., Hua, L."hClock gene expression in human colorectal carcinoma". Molecular Medicine Reports 8, no. 4 (2013): 1017-1022. https://doi.org/10.3892/mmr.2013.1643